Raphael Mechoulam
The Israeli organic chemist who isolated THC, co-discovered the endocannabinoid system, and shaped cannabis science for sixty years.
Mechoulam is the closest thing cannabis science has to a founding figure, and the credit is largely earned: he and his collaborators isolated THC's structure in 1964 and identified the first two endocannabinoids in the 1990s. But he's also been retrofitted into folklore he didn't author — the 'entourage effect,' for instance, was a real hypothesis he co-proposed, not a proven mechanism. Separate the documented chemistry from the marketing built on top of it.
Early life and path to chemistry
Raphael Mechoulam was born in 1930 in Sofia, Bulgaria, to a Sephardic Jewish family. His father was a physician; the family survived the Holocaust era in Bulgaria and emigrated to Israel in 1949 [1]. Mechoulam completed a degree in chemical engineering at a Soviet institute before returning to Israel, where he earned his PhD at the Weizmann Institute in 1958 with work on steroid chemistry [1]. He did postdoctoral research at the Rockefeller Institute in New York, then joined the Weizmann Institute and later the Hebrew University of Jerusalem, where he spent the rest of his career [2].
1964: Isolating THC
By the early 1960s, cannabis had been used medicinally and recreationally for millennia, but its active compound was unidentified. Morphine had been isolated from opium in 1804 and cocaine from coca in 1860 — cannabis was a conspicuous gap. Mechoulam later said he was 'surprised' that the chemistry of such a widely used plant was unknown [3].
Working with Yechiel Gaoni at the Weizmann Institute, Mechoulam obtained five kilograms of Lebanese hashish from the Israeli police — a now-famous anecdote he recounted in interviews [3]. In 1963 they reported the structure of cannabidiol (CBD), and in 1964 they published the isolation and structural elucidation of Δ⁹-tetrahydrocannabinol (THC) in the Journal of the American Chemical Society [4]. That 1964 paper is the foundational document of modern cannabinoid chemistry. Strong evidence
Mechoulam and colleagues then went on to synthesize THC and demonstrate, in monkey studies, that THC alone produced the characteristic intoxicating effects — establishing it as the principal psychoactive constituent [5].
1980s–1990s: The endocannabinoid system
After cannabinoid receptors CB1 (1988, Allyn Howlett's lab) and CB2 (1993, Sean Munro) were identified, an obvious question followed: what endogenous molecule binds them? Mechoulam's group answered first. In 1992, working with William Devane and Lumír Hanuš, they isolated an arachidonic acid derivative from pig brain that bound CB1, and named it anandamide after the Sanskrit ānanda, 'bliss' [6]. In 1995, his group (with Shimon Ben-Shabat) identified a second endocannabinoid, 2-arachidonoylglycerol (2-AG) [7].
These discoveries reframed cannabis pharmacology. THC was no longer just an exogenous oddity; it was mimicking a native signaling system involved in pain, appetite, mood, and immune function. The 'endocannabinoid system' as a concept is the direct product of this work. Strong evidence
The 'entourage effect': hypothesis vs. folklore
In a 1998 paper, Ben-Shabat, Mechoulam and colleagues proposed that inactive endogenous fatty-acid glycerols could potentiate the activity of 2-AG — they called this an 'entourage effect' [8]. The term was originally a narrow hypothesis about endocannabinoid pharmacology, not a claim about whole-plant cannabis.
The modern marketing usage — that the full spectrum of cannabis terpenes and minor cannabinoids produces qualitatively different effects than isolated THC — was popularized largely by neurologist Ethan Russo in a 2011 review [9]. Mechoulam himself supported the broader idea but acknowledged the clinical evidence remained thin. Treat 'entourage effect' as a plausible, partially supported hypothesis Weak / limited, not the settled fact dispensary signage often implies.
Later career and clinical translation
From the 2000s onward Mechoulam focused on therapeutic applications: CBD for epilepsy, cannabinoids in traumatic brain injury (his group's work on the synthetic cannabinoid dexanabinol), and the role of endocannabinoids in metabolic disease [2]. He was an early and persistent advocate for CBD research decades before the 2018 approval of Epidiolex for Dravet and Lennox–Gastaut syndromes — a regulatory milestone built in part on chemistry he started in 1963 [10].
He was vocal about the slow pace of cannabis clinical trials and the politicization of the field. In interviews he repeatedly distinguished between what the chemistry showed and what activists or marketers claimed it showed [3].
Death and legacy
Mechoulam died in Jerusalem on March 9, 2023, at age 92 [11]. Hebrew University announced his death; obituaries appeared in Nature, the New York Times, and major Israeli outlets [2][11].
His legacy is unusually well-documented because he kept publishing into his 90s and gave extensive on-record interviews. The honest summary: he did not 'discover cannabis,' he did not invent the entourage effect as a consumer concept, and he was not a clinician. He was an organic chemist who, with collaborators, mapped the molecular foundation that every subsequent cannabis researcher — and every dispensary marketing department — now stands on.
Sources
- Peer-reviewed Mechoulam, R. (2019). A delightful trip along the pathway of cannabinoid and endocannabinoid chemistry and pharmacology. Annual Review of Pharmacology and Toxicology, 60, 1–9.
- Reported Genzlinger, N. (2023, March 14). Raphael Mechoulam, 92, dies; Studied marijuana's components. The New York Times. ↗
- Reported Lewis-Kraus, G. (2019, May 6). The Great Pot Experiment. The New Yorker (interview material with Mechoulam). ↗
- Peer-reviewed Gaoni, Y., & Mechoulam, R. (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. Journal of the American Chemical Society, 86(8), 1646–1647.
- Peer-reviewed Mechoulam, R., Shani, A., Edery, H., & Grunfeld, Y. (1970). Chemical basis of hashish activity. Science, 169(3945), 611–612.
- Peer-reviewed Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946–1949.
- Peer-reviewed Mechoulam, R., Ben-Shabat, S., Hanuš, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., Pertwee, R. G., Griffin, G., Bayewitch, M., Barg, J., & Vogel, Z. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology, 50(1), 83–90.
- Peer-reviewed Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V., & Mechoulam, R. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 353(1), 23–31.
- Peer-reviewed Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
- Government U.S. Food and Drug Administration. (2018). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy [Press release]. ↗
- Reported Abbott, A. (2023). Raphael Mechoulam (1930–2023): chemist who unlocked secrets of cannabis. Nature, 616, 252.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.